NeurAxis, Inc., today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), covering two health insurers, with approximately 700,000 total members in Connecticut and Massachusetts.

NeurAxis, Inc., has been officially incorporated into newly released clinical practice guidelines issued by the leading pediatric academic society for the treatment of Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS).

NeurAxis, Inc., will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.

NeurAxis, Inc., today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share.

NeurAxis, Inc., today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules.

NeurAxis, Inc., awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

NeurAxis, Inc., today announced results for the first quarter 2025 for the period ended March 31, 2025.

Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time

NeurAxis, Inc., to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025

NeurAxis, Inc., today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.